Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597359 | 0.93 | CA12 (0.31) | CA12CA9 | |
| SCHEMBL2597443 | 0.92 | CA12 (0.30) | CA12CA9 | |
| SCHEMBL2597190 | 0.92 | NPC1 (0.32) | CA12CA9ALDH1A1 | |
| SCHEMBL2597329 | 0.91 | CA12 (0.32) | CA12CA9 | |
| SCHEMBL2599225 | 0.91 | CA12 (0.33) | CA12CA9 | |
| SCHEMBL2597072 | 0.90 | LIPG (0.37) | CA12CA9KDM4EALDH1A1GLA | |
| SCHEMBL2597442 | 0.89 | KDM4E (0.31) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2597152 | 0.87 | CA12 (0.35) | CA12CA9 | |
| SCHEMBL2597374 | 0.86 | CA12 (0.33) | CA12CA9LIPG | |
| SCHEMBL2597140 | 0.86 | CA12 (0.34) | CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | claimed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | claimed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | claimed |
| EP-2571865-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG | 2013-02-28 | — | — | US | disclosed |
| WO-2011144666-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053381-A1 | 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES | GRIK2, GRIK1, GRIK4 | CA12 1465/4885CA9 2087/4885KDM4E 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.